文献速递临床试验与 GCP

瑞升奇单抗对比乌司奴单抗治疗中重度克罗恩病

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
PubMed 文献 · N Engl J Med · 2024-01-01

这项3b期、多中心、开放标签、随机对照试验纳入对抗TNF治疗应答不足或不耐受的中重度克罗恩病患者,按标准剂量接受瑞升奇单抗或乌司奴单抗治疗48周。瑞升奇单抗第24周临床缓解非劣于乌司奴单抗,第48周内镜缓解优于乌司奴单抗,两组不良事件发生率相似。

要点

  • 第24周临床缓解率瑞升奇单抗58.6% vs 乌司奴单抗39.5%,校正差值18.4个百分点(95%CI 6.6至30.3),非劣效成立。
  • 第48周内镜缓解率瑞升奇单抗31.8% vs 乌司奴单抗16.2%,校正差值15.6个百分点(95%CI 8.4至22.9;P<0.001),优效成立。
  • 两组不良事件发生率看似相似。

核心结论

  • 在中重度克罗恩病且对抗TNF治疗应答不足或不耐受的患者中,瑞升奇单抗第24周临床缓解非劣于乌司奴单抗,第48周内镜缓解优于乌司奴单抗。

研究设计与样本

  • 3b期、多中心、开放标签、随机对照试验,终点评估采用盲法,患者按标准剂量接受瑞升奇单抗或乌司奴单抗治疗48周。

主要发现

  • 全意向性治疗疗效分析人群中,瑞升奇单抗组255例中230例(90.2%)完成全部 assigned 治疗,乌司奴单抗组265例中193例(72.8%)完成全部 assigned 治疗。
  • 第24周临床缓解(克罗恩病活动指数评分<150)瑞升奇单抗组58.6% vs 乌司奴单抗组39.5%,校正差值18.4个百分点(95%CI 6.6至30.3),非劣效成立。
  • 第48周内镜缓解(简化内镜评分≤4分、较基线下降≥2分且各单项评分均≤1分)瑞升奇单抗组31.8% vs 乌司奴单抗组16.2%,校正差值15.6个百分点(95%CI 8.4至22.9;P<0.001),优效成立。
  • 两组不良事件发生率看似相似。

关键数值与推荐

  • 临床缓解定义为克罗恩病活动指数评分<150(范围0至600,评分越高疾病活动越重),非劣效界值为10个百分点。
  • 内镜缓解定义为简化内镜评分≤4分、较基线下降≥2分且各单项评分均≤1分(范围0至56,评分越高越重)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown. METHODS: In this phase 3b, multicenter, open-label, randomized, controlled trial with blinded assessment of end points, patients with moderate-to-severe Crohn's disease who had had an inadequate response to anti-tumor necrosis factor (TNF) therapy or unacceptable side effects with such therapy were randomly assigned to receive risankizumab or ustekinumab at standard doses for 48 weeks. The two primary end points, which were tested sequentially, were clinical remission at week 24 (defined as a Crohn's Disease Activity Index score of <150 [range, 0 to 600, with higher scores indicating more severe disease activity]), which was analyzed in the first 50% of patients to complete the week 24 visit, with a noninferiority margin of 10 percentage points; and endoscopic remission at week 48 (defined as a score of ≤4, a decrease of ≥2 points from baseline, and no subscore >1 in any individual variable on the Simple Endoscopic Score for Crohn's Disease [range, 0 to 56, with higher scores indicating more severe disease]), which was analyzed for superiority in 100% of the patients. Safety was assessed in all patients who received at least one dose of risankizumab or ustekinumab. RESULTS: In the full intention-to-treat population for the efficacy analysis, 230 of 255 patients (90.2%) who received risankizumab and 193 of 265 patients (72.8%) who received ustekinumab completed all the assigned treatments. Both primary end points were met; risankizumab was noninferior to ustekinumab with respect to clinical remission at week 24 (58.6% vs. 39.5%; adjusted difference, 18.4 percentage points; 95% confidence interval [CI], 6.6 to 30.3) and superior to ustekinumab with respect to endoscopic remission at week 48 (31.8% vs. 16.2%; adjusted difference, 15.6 percentage points; 95% CI, 8.4 to 22.9; P<0.001). The incidence of adverse events appeared to be similar in the two groups. CONCLUSIONS: In this head-to-head clinical trial of risankizumab and ustekinumab involving patients with moderate-to-severe Crohn's disease who had had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy, risankizumab was noninferior to ustekinumab with respect to clinical remission at week 24 and superior with respect to endoscopic remission at week 48. (Funded by AbbVie; ClinicalTrials.gov number, NCT04524611.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. N Engl J Med. 2024. PMID: 39018531. doi:10.1056/NEJMoa2314585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。